If you haven’t had the chance yet, check out the article from the Economist “The first endometriosis drug in four decades is on the horizon” [1]. TLDR: The use of dichloroacetate (available as a generic) is being investigated by the University of Edinburgh as a treatment option for endometriosis. There is also a potential advancement for noninvasive diagnosis as well. The current diagnostic process is to guess based on symptoms, or verify via surgery.

Around 10% of women experience endometriosis in their lifetime. Currently, the only treatment options are NSAIDs for pain relief, birth control with limited effectiveness, and invasive surgery. Healthcare costs associated are in the tens of billions, and women experience pretty high losses in productivity [2]. I understand that the reality of healthcare economics is the majority of extensive clinical research is driven by for-profit pharmaceutical and medical device companies. 

Where I’m confused is why there has been no advancement from the pharma industry. This recent advancement is being led by academia with a generic drug. From the numbers, this appears to be a significant potential market. We know that in healthcare, women are less likely to receive pain relief [3], worse for women of color [4]. It’s really hard to avoid the conclusion that the female market is being ignored, again.

That said, I’m definitely celebrating the University of Edinburgh for pursuing this research, and hoping for positive outcomes.